Pharma Focus Europe

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Wednesday, January 11, 2023

Clearmind Medicine Inc., a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announced that it has successfully manufactured batches of its drug candidate, MEAI-based molecule CMND-100, for use in its first in-human clinical trial.

The trial will evaluate the psychedelic-derived drug candidate for the treatment of Alcohol Use Disorder (AUD).

“Having our drug candidate ready to be tested is a major milestone toward our first in-human clinical trial,” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer. “Our pre-clinical positive results indicated the potential of our unique treatment for AUD. We continue to execute the final steps necessary in order to commence our clinical program.”

The drug candidate was produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements.

magazine-slider-img
Thermo Fisher Scientific - mRNA ServicesWorld Orphan Drug Congress 2024World Vaccine Congress Europe 2024Advanced Therapies USA 2024
cytiva